Compare Lupin with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN vs AUROBINDO PHARMA - Comparison Results

LUPIN     Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN AUROBINDO PHARMA LUPIN/
AUROBINDO PHARMA
 
P/E (TTM) x 46.9 19.7 238.2% View Chart
P/BV x 4.3 4.3 101.2% View Chart
Dividend Yield % 0.5 0.2 203.3%  

Financials

 LUPIN   AUROBINDO PHARMA
EQUITY SHARE DATA
    LUPIN
Mar-20
AUROBINDO PHARMA
Mar-19
LUPIN/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs882830 106.3%   
Low Rs505527 95.8%   
Sales per share (Unadj.) Rs339.4333.9 101.6%  
Earnings per share (Unadj.) Rs-5.940.4 -14.7%  
Cash flow per share (Unadj.) Rs15.551.8 29.9%  
Dividends per share (Unadj.) Rs6.002.50 240.0%  
Dividend yield (eoy) %0.90.4 234.8%  
Book value per share (Unadj.) Rs276.7237.1 116.7%  
Shares outstanding (eoy) m453.00585.91 77.3%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x2.02.0 100.6%   
Avg P/E ratio x-116.616.8 -693.7%  
P/CF ratio (eoy) x44.813.1 342.0%  
Price / Book Value ratio x2.52.9 87.6%  
Dividend payout %-100.96.2 -1,628.7%   
Avg Mkt Cap Rs m314,201397,569 79.0%   
No. of employees `00018.317.9 102.5%   
Total wages/salary Rs m29,86825,849 115.6%   
Avg. sales/employee Rs Th8,400.610,956.9 76.7%   
Avg. wages/employee Rs Th1,632.01,447.7 112.7%   
Avg. net profit/employee Rs Th-147.21,324.3 -11.1%   
INCOME DATA
Net Sales Rs m153,748195,636 78.6%  
Other income Rs m4,8381,553 311.5%   
Total revenues Rs m158,585197,189 80.4%   
Gross profit Rs m24,84939,519 62.9%  
Depreciation Rs m9,7026,680 145.3%   
Interest Rs m3,6302,626 138.2%   
Profit before tax Rs m16,35531,767 51.5%   
Minority Interest Rs m427 14.4%   
Prior Period Items Rs m390-   
Extraordinary Inc (Exp) Rs m-7,521-881 854.0%   
Tax Rs m11,5717,269 159.2%   
Profit after tax Rs m-2,69423,645 -11.4%  
Gross profit margin %16.220.2 80.0%  
Effective tax rate %70.822.9 309.2%   
Net profit margin %-1.812.1 -14.5%  
BALANCE SHEET DATA
Current assets Rs m154,132153,645 100.3%   
Current liabilities Rs m92,252120,429 76.6%   
Net working cap to sales %40.217.0 237.1%  
Current ratio x1.71.3 131.0%  
Inventory Days Days82135 60.7%  
Debtors Days Days12964 203.0%  
Net fixed assets Rs m89,082103,909 85.7%   
Share capital Rs m906586 154.6%   
"Free" reserves Rs m124,461138,322 90.0%   
Net worth Rs m125,367138,908 90.3%   
Long term debt Rs m17,9331,800 996.5%   
Total assets Rs m249,839264,544 94.4%  
Interest coverage x5.513.1 42.0%   
Debt to equity ratio x0.10 1,104.2%  
Sales to assets ratio x0.60.7 83.2%   
Return on assets %0.49.9 3.8%  
Return on equity %-2.117.0 -12.6%  
Return on capital %8.723.8 36.6%  
Exports to sales %049.6 0.0%   
Imports to sales %018.8 0.0%   
Exports (fob) Rs mNA97,091 0.0%   
Imports (cif) Rs mNA36,741 0.0%   
Fx inflow Rs m51,45097,316 52.9%   
Fx outflow Rs m19,47040,589 48.0%   
Net fx Rs m31,98056,727 56.4%   
CASH FLOW
From Operations Rs m14,68816,220 90.6%  
From Investments Rs m11,070-28,768 -38.5%  
From Financial Activity Rs m-8,90619,191 -46.4%  
Net Cashflow Rs m16,8536,656 253.2%  

Share Holding

Indian Promoters % 46.6 54.1 86.1%  
Foreign collaborators % 0.2 0.0 -  
Indian inst/Mut Fund % 11.3 8.0 142.1%  
FIIs % 31.9 27.7 115.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.1 10.2 99.0%  
Shareholders   98,259 69,601 141.2%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN With:   BIOCON   CADILA HEALTHCARE  SUVEN LIFE SCIENCES  PANACEA BIOTECH  WOCKHARDT  

Compare LUPIN With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 257 Points Higher; Tata Steel & Hindalco Among Top Nifty Gainers(Closing)

Indian share markets witnessed positive trading activity throughout the day today and ended higher.

Related Views on News

LUPIN 2019-20 Annual Report Analysis (Annual Result Update)

Dec 7, 2020 | Updated on Dec 7, 2020

Here's an analysis of the annual report of LUPIN for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

LUPIN Announces Quarterly Results (2QFY21); Net Profit Up 271.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, LUPIN has posted a net profit of Rs 2 bn (up 271.3% YoY). Sales on the other hand came in at Rs 38 bn (down 12.0% YoY). Read on for a complete analysis of LUPIN's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 25.6% (Quarterly Result Update)

Sep 15, 2020 | Updated on Sep 15, 2020

For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

LUPIN Announces Quarterly Results (1QFY21); Net Profit Down 64.2% (Quarterly Result Update)

Aug 18, 2020 | Updated on Aug 18, 2020

For the quarter ended June 2020, LUPIN has posted a net profit of Rs 1 bn (down 64.2% YoY). Sales on the other hand came in at Rs 35 bn (down 20.2% YoY). Read on for a complete analysis of LUPIN's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)

Jun 5, 2020 | Updated on Jun 5, 2020

For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Sell in May and Go Away?(Fast Profits Daily)

Apr 28, 2021

Does the concept of selling stocks in the month of May, work in the Indian market?

This Fund Manager Has Taken the World by Storm. Will You Invest With Her?(Profit Hunter)

Apr 26, 2021

Should you invest with this Rockstar fund manager who has outperformed in a big way?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN SHARE PRICE


May 7, 2021 (Close)

TRACK LUPIN

COMPARE LUPIN WITH

MARKET STATS